AIM ImmunoTech (LTS:0A4Y) Total Payout Ratio : 0.05 (As of Apr. 28, 2025)

View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

AIM ImmunoTech's current Total Payout Ratio is 0.05.

AIM ImmunoTech Total Payout Ratio Historical Data

The historical data trend for AIM ImmunoTech's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Total Payout Ratio Chart

AIM ImmunoTech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Payout Ratio

Get a 7-Day Free Trial

4.25

0.68

0.02

0.05

AIM ImmunoTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Payout Ratio	Get a 7-Day Free Trial															0.01	0.06	0.29	-	0.01

Competitive Comparison of AIM ImmunoTech's Total Payout Ratio

For the Biotechnology subindustry, AIM ImmunoTech's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Total Payout Ratio falls into.

Save Embed

;

Save Embed

;

AIM ImmunoTech Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

AIM ImmunoTech's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.892	+	0)	/	-17.32
	=	0.05

AIM ImmunoTech's Total Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Total Payout Ratio	=	- (Repurchase of Stock	+	Issuance of Stock	+	Cash Flow for Dividends)	/	Net Income
	=	- (0	+	0.032	+	0)	/	-5.967
	=	0.01

AIM ImmunoTech Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » Total Payout Ratio

Comparable Companies

Traded in Other Exchanges

AIMI:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines